Elcelyx Therapeutics

15 articles about Elcelyx Therapeutics

• Elcelyx Therapeutics Reports Positive Results In Phase 2b Study Of Metformin Delayed Release In Type 2 Diabetes

  11/10/2016

• Elcelyx Therapeutics Elects Sandy Mahatme To Board Of Directors

  10/12/2016

• Elcelyx Therapeutics Completes Enrollment In Phase 2b Clinical Trial Of Metformin Delayed Release For Type 2 Diabetes

  5/25/2016

• SoCal's Elcelyx Therapeutics Reels in $40 Million

  10/1/2015

• Elcelyx Therapeutics Announces Positive Results in Phase 2b Study of NewMet in Type 2 Diabetes

  10/21/2013

• Elcelyx Therapeutics to Present Clinical Data on NewMet in Type 2 Diabetes at the 49th Annual European Association for the Study of Diabetes Meeting

  9/17/2013

• NaZura BioHealth Spun-Out From Elcelyx Therapeutics to Advance Lovidia for Weight Management

  9/4/2013

• Elcelyx Therapeutics' NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study

  9/4/2013

• Elcelyx Therapeutics' Study Shows NewMet Has Better Glucose-Lowering Effects Than Metformin

  6/24/2013

• Elcelyx Therapeutics to Present Clinical Data on NewMet&#0153 in Type 2 Diabetes at the 2013 American Diabetes Association Scientific Sessions

  6/17/2013

• Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes

  5/20/2013

• Elcelyx Therapeutics Closes on $20 Million to Advance Appetite-Control Compounds

  2/14/2013

• Elcelyx Therapeutics Raises $4 Million

  8/13/2012

• Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors

  8/13/2012

• Startup Elcelyx Therapeutics Raises $1.2 Million

  3/19/2010